Advanced Science, Volume 13, Issue 25, 4 May 2026.The schematic diagram illustrates the roles of novel immune checkpoints, immunomodulatory factors, cell death and multimodal technologies in cancer immunotherapy. Abstract Cancer immunotherapy has redefined cancer treatment. However, the molecular and cellular basis of immune evasion and therapeutic resistance remains incompletely understood.
Fangquan Chen +7 more
wiley +1 more source
A Versatile Polymer‐Based In Situ Nanovaccine to Boost Cancer Immunotherapy
Aggregate, Volume 7, Issue 5, May 2026.A polymer‐based in situ nanovaccine (PCR‐NPs) orchestrates a powerful antitumor immune cascade via integrated antigen release, capture, and lymph nodes transport, eliciting potent CD8+ T cell responses that drive significant tumor inhibition and prolonged mice survival in murine tumor models.
Qi‐Song Tong +6 more
wiley +1 more source
6-Phosphogluconate dehydrogenase promotes mitochondrial fusion and immune suppression in tumor-associated monocytic suppressor cells. [PDF]
Nat CommunDaneshmandi S +13 more
europepmc +1 more source
The Immune Landscape of Acral Melanoma: From Basic to Clinical
Cancer Medicine, Volume 15, Issue 5, May 2026.ABSTRACT Background Acral melanoma (AM) is an aggressive melanoma subtype with poor prognosis and limited response to immune checkpoint inhibitors (ICIs). Despite increasing research efforts, the mechanisms underlying therapeutic resistance remain incompletely understood.
Lihong Jiang, Zhaotian Zhang
wiley +1 more source
CD300ld blockade overcomes PMN-MDSC-mediated vaccine resistance in advanced tumors. [PDF]
J Immunother CancerWang X +8 more
europepmc +1 more source
Immunotherapy and Breast Reconstruction: Opportunities, Challenges, and Future Directions
Cancer Medicine, Volume 15, Issue 5, May 2026.ABSTRACT Immunotherapy is transforming breast cancer management, but it also presents new challenges for surgical and reconstructive practice. This review summarizes current evidence on immune checkpoint inhibitors, perioperative safety, and immune‐related adverse events, highlighting their impact on surgical timing, postoperative recovery, and ...
Shuang Li +6 more
wiley +1 more source
Myeloid-derived suppressor cells and regulatory T cells in colorectal cancer: a synergistic immunosuppressive axis and emerging therapeutic opportunities. [PDF]
Front ImmunolZhang W +8 more
europepmc +1 more source
Cancer Medicine, Volume 15, Issue 5, May 2026.ABSTRACT Ovarian Cancer (OC), the deadliest gynecological malignancy, poses a major therapeutic challenge in advanced stages owing to its high recurrence rate and metastatic potential. In this regard, it is noteworthy that immunotherapy has recently gained significant attention in OC treatment, a phenomenon attributable to notable advances in over‐the ...
Liying Wang +4 more
wiley +1 more source
The immunological fitness of NSCLC patients drives the response to anti-PD1-based immunotherapy regardless of age. [PDF]
J Transl MedTuosto L +14 more
europepmc +1 more source
Nanotechnology Meets Immunotherapy: Crosstalks Against Cancer
Immunity, Inflammation and Disease, Volume 14, Issue 5, May 2026.ABSTRACT Background The convergence of nanotechnology and immunotherapy has ushered in a transformative era in cancer treatment, offering new strategies to overcome pharmacokinetic limitations and immune evasion associated with conventional therapies. While immunotherapy, spanning checkpoint inhibitors, adoptive cell transfer, and cancer vaccines, has ...
Nima Javanmehr +4 more
wiley +1 more source